Sales of the firm's infectious disease and women's health products were credited with driving the year-over-year increase in revenues.
The firm launched the multiplex PCR-based test this week on its Spartan Cube platform to support patient enrollment in Alzheimer's clinical trials.
Illumina is preparing to submit its first pre-market application to the FDA for a companion diagnostic developed with Amgen for the colorectal cancer drug Vectibix.
The company was established earlier this year by the co-founders of reproductive genetics firm Recombine, which was sold to CooperSurgical in May.
The firm, as indicated by its agreement to acquire Sequenom, is optimistic about the prospects for NIPT.
In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.
At Nature, John Wilbanks and Eric Topol call for openness in health data.
Law.com predicts that genomic and genetic testing will become common in toxic tort cases.
A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.